Navigation Links
Trubion Announces Dates for Fourth-Quarter and Year-Ended 2008 Earnings Conference Call

SEATTLE, March 5 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced that it plans to issue earnings results for the fourth quarter and year ended Dec. 31, 2008, after the close of market on March 12, 2009. The company's earnings conference call will take place March 12, 2009, at 2 p.m. Pacific Time, 5 p.m. Eastern Time.

Both live events will be available for viewing on Trubion's website at

Fourth-Quarter and Year-Ended 2008 Earnings Conference Call: 2 p.m. PDT/5 p.m. EDT, March 12, 2009

Trubion will host a conference call and webcast to discuss its fourth-quarter and year-ended 2008 financial results and provide an update on business activities. The call will be held March 12 at 2 p.m. Pacific Time, 5 p.m. Eastern Time. The live event will be available from Trubion's website at, or by calling (719) 325-4831 or (877) 852-6579. A replay of the discussion will be available beginning 8 p.m. Eastern Time from Trubion's website or by calling (719) 457-0820 or (888) 203-1112 and entering 5983743. The telephone replay will be available until March 19, 2009.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed SMIP therapeutics such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the company's Wyeth collaboration. Trubion's product pipeline also includes Trubion's proprietary product candidate, TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies that is currently in Phase 1/2 clinical evaluation. In addition to Trubion's current clinical stage product pipeline, the company is also developing additional product candidates that build on its product development experience. More information is available in the investors section of Trubion's website:


    Jim DeNike
    Senior Director, Corporate Communications
    Trubion Pharmaceuticals Inc.
    (206) 838-0500

    Waggener Edstrom Worldwide Healthcare
    Amy Petty
    Senior Account Executive
    (617) 576-5788

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Trubion Pharmaceuticals Provides Announcement Dates for Third-Quarter and Nine Months Earnings Conference Call
2. Trubion Pharmaceuticals Announces Appointment of New Chief Medical Officer
3. Trubion Pharmaceuticals Provides Announcement Dates for Second Quarter and First Six Months Earnings Conference Call
4. Trubion Pharmaceuticals Announces Dates for Fourth-Quarter and Year-End 2007 Earnings Conference Call
5. Trubion Announces Presentations at Upcoming Investor Conferences
6. Karmanos Cancer Institute Announces Interim Leadership
7. Sysmex Corporation Announces Organizational Changes
8. IDRI Announces Appointment of Dr. Karen Auditore-Hargreaves as SVP, Scientific Affairs
9. Kensey Nash Announces Appointment of Chief Financial Officer
10. HMS Holdings Corp. Announces Executive Promotions
11. Solta Medical, Inc. Announces State-of-the-Art Aesthetic Center
Post Your Comments:
(Date:10/13/2017)... ... ... As health professionals work to improve their approach to healthcare, there is ... than filling out a survey; in many cases health professionals and patients are working ... and research on the importance of active engagement with patients and members of the ...
(Date:10/13/2017)... , ... October 13, 2017 ... ... of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ... on guideline updates for the primary prevention of cardiovascular diseases during the ...
(Date:10/13/2017)... ... , ... Ellevate Network, the leading network for professional women, brought together some ... at their inaugural Summit in New York City in June. The event was livestreamed ... over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... ... 2017 , ... “The Journey: From the Mountains to the Mission Field”: the ... in the Philippines. “The Journey: From the Mountains to the Mission Field” is the ... She has taught all ages and currently teaches a class of ladies at her ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)...   West Pharmaceutical Services, Inc. (NYSE: WST), ... administration, today shared the results of a study highlighting ... intradermal administration of polio vaccines. The study results were ... 2017 by Dr. Ondrej Mach , Clinical Trials ... (WHO), and recently published in the journal Vaccine. ...
(Date:10/4/2017)... South Korea , Oct. 4, 2017  South ... its next-generation CPR training aide "cprCUBE" on Kickstarter. The ... chest compression during cardiac arrests with better efficiency compared ... It also offers real-time feedback on efficacy of the ... The crowdfunding campaign has a goal to raise $5,000. ...
(Date:10/2/2017)... 2017 Diplomat Pharmacy, Inc. (NYSE: ... Consulting, LLC , and named its founder as Diplomat,s ... Tennessee , will operate under Diplomat ... service offerings for health care partners to include IT ... "In an interoperable world, technology delivers comprehensive ...
Breaking Medicine Technology: